Aveni Foundation

16/11/2025

https://www.youtube.com/watch?v=b7azNAQuX6Y

"I absolutely do believe that DeltaRex has saved my life…"

"Thankfully it's one of these really kind treatments that have zero side effects and it's something I could just continue and feel really well on…"

"It's completely stabilized me beyond what I could have dreamed of…"

"This isn't just about me, it's about… anyone dealing with a stage 4 incurable cancer. They need hope. And DeltaRex just feels so hopeful, especially because really when I look back on my whole journey—which now has been a ten-year cancer journey—my whole ethos really has been around an integrative approach, and that doesn't mean you conquer and divide western and eastern, it means it needs an innovative approach, and DeltaRex fits so perfectly into that."

"I truly believe that DeltaRex will continue to keep me well and alive."

—Hope Pearce (patient)

Hope shares about the vital role DeltaRex-G (DNG64-CAR-V) has played in getting and keeping her well. Sarcoma Oncology Center, Santa Monica CA. October 2024. November 2025: Hope continues to receive DeltaRex-G with Dr. Stefaan van Gool at IOZK, Cologne, Germany.

see testimonial at: avenifoundation.org/news-notes

Hope shares about the vital role DeltaRex-G (DNG64-CAR-V) has played in getting and keeping her well. Sarcoma Oncology Center, Santa Monica CA. October 2024....

18/12/2024

https://youtu.be/8uNNirbNNfY
Vaishali Kumar, MBBS, Sarcoma Oncology Research Center, Santa Monica, CA, discusses findings from an analysis of CCNG1 expression in 137 patients across various cancer types treated with DRG-101, a tumor-targeted retrovector. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

Vaishali Kumar, MBBS, Sarcoma Oncology Research Center, Santa Monica, CA, discusses findings from an analysis of CCNG1 expression in 137 patients across vari...

13/06/2024

Welcome to our fundraising page for Aveni Foundation! Our mission is to accelerate the development of gene-targeted therapies for metastatic cancers, Parkinson's disease, and other unmet medical needs. With your support, we can fund innovative research and clinical trials that have the potential to....

02/01/2024

ANNOUNCEMENT (December 14, 2023): Sarcoma Oncology Center Leverages BostonGene’s AI-driven Molecular and Immune Profiling Platform to Identify Novel Treatment Options for Patients with Advanced Cancers

"Our partnership with BostonGene provides us with an AI-driven, molecular perspective of the dynamic tumor microenvironment and immune landscape, thereby expanding the treatment horizons for our patients."
- Erlinda Gordon, MD

"This collaboration has broadened our cancer treatment options, as BostonGene is the only molecular profiling company reporting on the CCNG1 expression in tumors."
- Sant P. Chawla, MD

https://bostongene.com/?press=sarcoma-oncology-center-leverages-bostongenes-ai-driven-molecular-and-immune-profiling-platform-to-identify-novel-treatment-options-for-patients-with-advanced-cancers

02/01/2024

ANNOUNCEMENT (December 11, 2023): Aveni Foundation Publishes "From Mendel to Gene Therapy" Mapping the History of Genetic Medicine

Aveni Foundation and Cancer Center of Southern California proudly announce the publication of “From Mendel to Gene Therapy” by Jeffrey S, Brigham DA, Chawla SP, Federman N, Hall FL and Gordon EM (Anticancer Res.43:4257-4261, 2023). In this article, Jeffrey et al. map out the history of genetic medicine from Gregor Mendel, whose experimentation in the field of heredity laid the groundwork for modern genetics, consequently paving the way for gene therapy.

The 20th of July 2022 marked 200 years since the birth of Gregor Mendel, whose experimentation in the field of heredity laid the groundwork for modern genetics, consequently paving the way for gene therapy. Over the past bicentennial, the field of genetics has evolved from the study of inheritable

25/10/2023

"Since DeltaRex-G reduces stroma production as well as kills cancer cells, DeltaRex-G enhances immune cell trafficking in the tumor microenvironment, therefore serving as an immune modulator.”— Sant P. Chawla, MD

PRESENTED BY DR. SANT P. CHAWLA AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY

20/10/2023

Dr. Sant Chawla of Cancer Center of Southern California speaks about his clinical experience with DeltaRex-G (formerly: Rexin-G) at Aveni Foundation's "An Evening with Gustavo Santaolalla" on September 30, 2023.

13/10/2023

Onward...

13/10/2023

On behalf of Aveni Foundation and our Board of Directors, I would like to thank all who attended “An Evening with Gustavo Santaolalla,” and who contributed their talents and resources in celebration, in tribute, and in support of our mission: Broadly, to expedite the development of gene-targeted technologies for cancer and Parkinson’s disease, and specifically, to resurrect DeltaRex-G for the benefit of cancer patients worldwide. Together, we made this event a success! - Dr. Erlinda M Gordon

.rainone

13/10/2023

Blessed

13/10/2023

Honorable Marc Aveni speaks about his uncle, Father Joseph Aveni

12/10/2023

Norma Yaeger, author of Breaking Down the Walls; friend, business advisor, and Aveni Foundation Development Committee member